WO2010119455A3 - An injectable sustained release pharmaceutical composition - Google Patents

An injectable sustained release pharmaceutical composition Download PDF

Info

Publication number
WO2010119455A3
WO2010119455A3 PCT/IN2010/000243 IN2010000243W WO2010119455A3 WO 2010119455 A3 WO2010119455 A3 WO 2010119455A3 IN 2010000243 W IN2010000243 W IN 2010000243W WO 2010119455 A3 WO2010119455 A3 WO 2010119455A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
sustained release
release pharmaceutical
injectable sustained
injectable
Prior art date
Application number
PCT/IN2010/000243
Other languages
French (fr)
Other versions
WO2010119455A2 (en
Inventor
Ajay Jaysingh Khopade
Mayur Sankalia
Subhas Balaram Bhowmick
Rajamannar Thennati
Original Assignee
Sun Pharma Advanced Research Company Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Company Ltd. filed Critical Sun Pharma Advanced Research Company Ltd.
Publication of WO2010119455A2 publication Critical patent/WO2010119455A2/en
Publication of WO2010119455A3 publication Critical patent/WO2010119455A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Abstract

The present invention relates to an injectable pharmaceutical composition comprising antipsychotic agents having basic groups.
PCT/IN2010/000243 2009-04-15 2010-04-15 An injectable sustained release pharmaceutical composition WO2010119455A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN978MU2009 2009-04-15
IN978/MUM/2009 2009-04-15

Publications (2)

Publication Number Publication Date
WO2010119455A2 WO2010119455A2 (en) 2010-10-21
WO2010119455A3 true WO2010119455A3 (en) 2011-01-27

Family

ID=42982942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000243 WO2010119455A2 (en) 2009-04-15 2010-04-15 An injectable sustained release pharmaceutical composition

Country Status (1)

Country Link
WO (1) WO2010119455A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121706A1 (en) * 2009-04-10 2012-05-17 Tufts Medical Center, Inc. PAR-1 Activation by Metalloproteinase-1 (MMP-1)
WO2014017594A1 (en) * 2012-07-26 2014-01-30 久光製薬株式会社 Adhesive patch
US20170231957A1 (en) * 2014-08-14 2017-08-17 Alrise Biosystems Gmbh Injectable formulations of asenapine
EP3307245A1 (en) 2015-06-11 2018-04-18 Alrise Biosystems GmbH Process for the preparation of drug loaded microparticles
CN104940150B (en) * 2015-06-16 2020-11-20 黑龙江大学 Preparation method of paliperidone sustained-release microsphere injection
CN110087641B (en) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutene
JP7236389B2 (en) 2016-12-20 2023-03-09 エルテーエス ローマン テラピー－ジステーメ アーゲー Transdermal therapeutic system containing asenapine
JP2020525545A (en) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー Transdermal therapeutic system containing asenapine and silicone-acrylic hybrid polymer
CN110958876B (en) 2018-06-20 2020-12-18 罗曼治疗系统股份公司 Transdermal therapeutic system comprising asenapine
WO2020091845A1 (en) * 2018-10-29 2020-05-07 University Of South Florida Lithium cholesterol compositions and methods of treatment for alzheimer's disease and neurological disorders
EP4319721A1 (en) * 2021-04-07 2024-02-14 Proneurogen, Inc. Extended-release injectable gel formulations containing angiotensin-(1-7) oligopeptides or variants thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132007A1 (en) * 1998-03-18 2002-09-19 University Technology Corporation Sustainded-release composition including amorphous polymer
WO2005032523A1 (en) * 2003-09-30 2005-04-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132007A1 (en) * 1998-03-18 2002-09-19 University Technology Corporation Sustainded-release composition including amorphous polymer
WO2005032523A1 (en) * 2003-09-30 2005-04-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations

Also Published As

Publication number Publication date
WO2010119455A2 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
WO2010119455A3 (en) An injectable sustained release pharmaceutical composition
EP2240022A4 (en) Pharmaceutical compositions
GB0814695D0 (en) Pharmaceutical compositions
IL228817A0 (en) Pharmaceutical composition
EP2373681A4 (en) Pharmaceutical compositions
WO2012042371A3 (en) Pharmaceutical composition
AP2010005380A0 (en) Extracellular matrix compositions.
PT2323623T (en) Pharmaceutical compositions
ZA201109138B (en) Pharmaceutical composition having improved solubility
ZA201102715B (en) Solid pharmaceutical composition
IL208387A0 (en) Pharmaceutical composition
ZA201100871B (en) Solid pharmaceutical composition
ZA201006224B (en) Pharmaceutical composition
UA96476C2 (en) Pharmaceutical composition comprising irbesartan
PL2405753T3 (en) Insect-repellent composition
ZA201100529B (en) Solid pharmaceutical composition comprising exemestane
GB0917359D0 (en) Pharmaceutical composition
IL206487A0 (en) Pharmaceutical compositions
EP2311493A4 (en) Cytotoxic composition
GB0817969D0 (en) Pharmaceutical composition
HK1182939A1 (en) Stable pharmaceutical composition
GB0800659D0 (en) Pharmaceutical Compositions
EP2327671A4 (en) Cement-setting-time accelerator compositions
AU2008902603A0 (en) Injectable Formulations
IL199679A0 (en) Injectable pharmaceutical composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10764178

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10764178

Country of ref document: EP

Kind code of ref document: A2